Akaal Pharma is a clinical-stage drug discovery and development biopharmaceutical company focused on developing novel drugs for the treatment of inflammation and immune diseases. Akaal has created a pipeline of new small molecule drugs for the treatment of Psoriasis, Atopic Dermatitis, Multiple Sclerosis (MS), Ulcerative Colitis (UC) and Rheumatoid Arthritis (RA). Akaal Pharma applies its proprietary medicinal chemistry and drug discovery platform coupled with broad and in-depth drug discovery and development expertise of our leadership team. Akaal Pharma has strong portfolio of intellectual property/patents on its internally discovered drug candidates. Several patents have been issued including in the US, Australia and New Zealand. The remaining patents to be issued in Europe, Japan, China, India and other countries are in the process. Akaal Pharma owns 100% of its intellectual property/patents.
Akaal Pharma has successfully completed a Phase-1 clinical trial of its First-in-Class Topical treatment for mild-to-moderate Psoriasis and is initiating a multicentre Phase-2 clinical trial for the topical treatment of mild-to-moderate Psoriasis in early Q2' 2015.
Akaal Pharma's is also developing novel, safer and effective small molecule oral drugs for the treatment of MS, UC and RA.
Akaal Pharma is developing novel, safer and highly effective drug candidates for the treatment of diseases with significantly large unmet medical need. Akaal Pharma's drug pipeline contains innovative new small molecule drugs for the treatment of Psoriasis, Atopic Dermatitis, Multiple Sclerosis (MS) and Ulcerative Colitis (UC). Akaal Pharma's business strategy is to partner its proprietary drug candidates with pharmaceutical and biotech companies for clinical development, manufacturing and commercialization of its novel drugs in exchange for upfront fees, research and development funding, milestone payments and potential royalties on product sales. Please contact Akaal Pharma for further details on various partnering opportunities.